MSF Demands Affordable Access to Key HIV Prevention Drug

Doctors Without Borders (MSF) is demanding a drastic price reduction for the long-acting HIV prevention drug lenacapavir, calling for generic production to hit a target of $40 per person per year as the International AIDS Conference opens in Rio de Janeiro, according to the medical humanitarian organization.

Gilead Pricing Sparks Global Access Debate

US pharmaceutical manufacturer Gilead currently charges $28,000 for a one-year supply of lenacapavir in the United States, according to MSF figures. That price applies strictly to individuals already living with HIV who require treatment, rather than uninfected populations seeking prevention. Global health advocates argue that this high cost structure makes the medication unaffordable for public health care systems operating in low- and middle-income countries.

“No one should be excluded from HIV prevention simply because a medicine is being kept artificially expensive,” said Melissa Scharwey, a global health expert at MSF, framing the access barrier as a critical challenge for international health equity.

Shifting Infection Rates and Funding Shortfalls

The demand for affordable access arrives as global health efforts face severe financial constraints. International health funding dedicated to combating HIV is experiencing a sharp decline, putting ongoing prevention and treatment programs under immense pressure, according to the German AIDS Action Alliance.

At the same time, the geography of the epidemic is changing. For the first time, data from the German AIDS Action Alliance shows that more than half of all new HIV infections globally now occur outside sub-Saharan Africa. Worldwide, approximately 1.2 million people acquire new HIV infections each year, while roughly 570,000 individuals die from AIDS-related illnesses.

International AIDS Conference Focuses on Solutions

The International AIDS Society is organizing the ongoing conference in Rio de Janeiro, which runs through Friday. Public health officials, researchers, and activists are using the gathering to address pricing models, production barriers, and the rollout of long-acting prevention tools like twice-yearly lenacapavir injections.

Frequently Asked Questions

What is lenacapavir used for?

Lenacapavir is utilized for treating individuals already living with HIV and is being positioned as an option for pre-exposure prophylaxis (PrEP) to prevent new infections.

How often is lenacapavir administered for prevention?

Unlike traditional oral PrEP that requires daily pills, lenacapavir is administered via injections just twice a year, according to medical reports.

Why is MSF demanding a $40 price point?

MSF argues that Gilead’s US price of $28,000 is unsustainable for healthcare systems in developing nations, pushing for open generic production and a target cost of $40 per person annually to ensure broad global access.